Menu
Search
|

Menu

Close
X

SIGA Technologies Inc SIGA.OQ (NASDAQ Stock Exchange Global Market)

6.24 USD
-0.11 (-1.73%)
As of Apr 12
chart
Previous Close 6.35
Open 6.34
Volume 9,300
3m Avg Volume --
Today’s High 6.34
Today’s Low 6.24
52 Week High 6.35
52 Week Low 5.70
Shares Outstanding (mil) 78.91
Market Capitalization (mil) 260.40
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY17
12
FY16
15
FY15
8
EPS (USD)
FY17
-0.494
FY16
-0.698
FY15
-0.732
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.74
Price to Sales (TTM)
vs sector
12.24
5.71
Price to Book (MRQ)
vs sector
--
5.37
Price to Cash Flow (TTM)
vs sector
--
23.32
Total Debt to Equity (MRQ)
vs sector
--
16.45
LT Debt to Equity (MRQ)
vs sector
--
12.18
Return on Investment (TTM)
vs sector
-56.30
14.38
Return on Equity (TTM)
vs sector
--
16.07

EXECUTIVE LEADERSHIP

Eric Rose
Executive Chairman of the Board, Since 2016
Salary: $743,130.00
Bonus: --
Phillip Gomez
Chief Executive Officer, Director, Since 2016
Salary: --
Bonus: --
Daniel Luckshire
Chief Financial Officer, Executive Vice President, Secretary, Since 2011
Salary: $437,091.00
Bonus: --
Dennis Hruby
Chief Scientific Officer, Vice President, Since 2000
Salary: $530,450.00
Bonus: --
James Antal
Independent Director, Since 2004
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

27 E 62nd St
NEW YORK   NY   10065-8014

Phone: +1212.6729100

SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company's lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.

SPONSORED STORIES